The triazolo-methyl tetrahydrobenzofuran oxime ether isomers were prepared through Cu (II)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction in a high-yielding three-step reaction sequence under mild conditions. All of the intermediates and target compounds were characterized by NMR, IR, ESI-MS and elemental analysis. Thein vitroanti-ulcer activity evaluation indicated the (Z)-oxime isomer of triazolo-methyl tetrahydrobenzofuran oxime ether exhibited most potent H+/K+-ATPase inhibitory effect with the IC50˰̵̱̼͆ͅ˰̶̿˰̅˾́̅˰μ̝˾ These compounds could be potentially used as anti-ulcer agents for the treatment of acid related diseases.

A pair of triazole-linked bistetrahydrobenzofuran derivatives were prepared in high yields through Cu (II)-catalyzed click reaction under mild conditions. All of the intermediates and target compounds were characterized by NMR, IR, ESI-MS and elemental analysis. Thein vitroH+/K+-ATPase inhibitory effect for the target compounds were also evaluated by MTT methods, and the (E)-isomer of the bistetrahydrobenzofurans exhibited the better H+/K+-ATPase inhibitory activities than the commercial omeprazole with the IC50of 37.90 μM. The bioactive compound might be potentially used as anti-ulcer agents in the treatment of acid-related diseases.

Six 6,6-dimethyl-2-phenyl-6,7-dihydrobenzofuran-4(5H)-one oxime derivatives were synthesized, characterized and evaluated as potential anti-ulcer agents. Most of the target compounds exhibited better H+/K+-ATPase inhibitory activity than commercial revaprazan, and both of the two O-propyl oxime ethers displayed the most potent activities with IC50˰̵̱̼͆̓ͅ˰̵̼̓̓˰̸̱̈́̾˰́̀˰μ̝˾ These compounds could be potentially used for the treatment of ulcer disease.

Three pairs of 2-phenyl-6,7-dihydrobenzofuran-4(5H)-one oxime and corresponding oxime ether isomers were synthesized and separated as potential anti-ulcer agent. Their structures were characterized by NMR, IR, ESI-MS and elemental analysis. Preliminarily H+/K+-ATPase activity evaluation indicated that all the target compounds had a better inhibitory effect than the commercial omeprazole with the IC50 of 2.0~30.0 μM.